MPAM
PHAT icon

Monarch Partners Asset Management’s Phathom Pharmaceuticals PHAT Stock Holding History

Monarch Partners Asset Management’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-21,325
Closed -$782K – 204
2020
Q3 		$782K Sell
21,325
-403
-2% -$14K 0.18% 134
2020
Q2 		$715K Buy
+21,728
New +$835K 0.17% 116

Other funds holding PHAT

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Monarch Partners Asset Management's PHAT Position: Q4 2020 in Review

Monarch Partners Asset Management sold out of Phathom Pharmaceuticals (PHAT) in Q4 2020, closing a stake of 21,325 shares — an estimated $782K sold.

Monarch Partners Asset Management first reported a position in PHAT in Q2 2020 and held it in 2 quarters. The position peaked at $782K in Q3 2020. 76 funds tracked by Wall St. Rank hold PHAT as of Q4 2020.

  • Monarch Partners Asset Management reported no remaining Phathom Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Monarch Partners Asset Management sold 21,325 Phathom Pharmaceuticals shares in Q4 2020, an estimated $782K.
  • Monarch Partners Asset Management first reported a position in Phathom Pharmaceuticals in Q2 2020 and held it in 2 quarters.
  • Monarch Partners Asset Management's Phathom Pharmaceuticals position peaked at $782K in Q3 2020.
  • 76 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q4 2020.

Based on Monarch Partners Asset Management's 13F filing for Q4 2020, filed 4 Feb 2021.